Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer

Inclusion Criteria: * Pathologically documented pancreatic adenocarcinoma deemed unresectable due to local involvement of vessels or organs * Patients with a clear clinical diagnosis of localized pancreatic cancer deemed unresectable, who have undergone at least 2 biopsies which were not diagnostic of adenocarcinoma, may be entered at the discretion of the principal investigator. * No prior chemotherapy or abdominal radiation therapy. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 * Clinically measurable or evaluable disease. * Life expectancy of at least 12 weeks. * Adequate bone marrow reserve, granulocyte count \>= 1500/uL, platelet count \>= 100,000/uL, hemoglobin \>= 9 g/dL. * Adequate renal function with creatinine =\< 1.5 times upper limit of normal (ULN) * Adequate biliary function with bilirubin \< 3.0 g/dL (including patients who have been bypassed or treated with percutaneous drainage), serum glutamic pyruvic transaminase (SGPT) (alanine transaminase) =\< 2.5 * Age \> 18 years * Signed informed consent. * No known allergy to one of the study drugs * For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception * No prior malignancy within last 5 years * No central nervous system metastases * No peripheral neuropathy \> grade2 * No other serious concomitant illness Exclusion Criteria: * Active infection or uncontrolled infection * Presence of metastatic disease. * Inadequate organ function as discussed above. * Pregnancy * Serious concomitant systemic disorder. * Use of any investigational agent within a month of treatment